DiaSorin S.p.A. (OTCMKTS:DSRLF - Get Free Report) saw a large growth in short interest in May. As of May 31st, there was short interest totalling 247,200 shares, a growth of 68.9% from the May 15th total of 146,400 shares. Approximately 0.5% of the company's stock are sold short. Based on an average trading volume of 0 shares, the short-interest ratio is currently ∞ days.
DiaSorin Trading Down 3.2%
OTCMKTS DSRLF traded down $3.64 on Friday, hitting $108.66. 1,864 shares of the stock were exchanged, compared to its average volume of 296. DiaSorin has a fifty-two week low of $100.01 and a fifty-two week high of $112.30. The company has a 50-day moving average price of $106.94 and a 200-day moving average price of $106.65.
DiaSorin Company Profile
(
Get Free Report)
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DiaSorin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DiaSorin wasn't on the list.
While DiaSorin currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
